MedTrace Logo

PDD in Type 2 Diabetes w/wo Diastolic Dysfunction

NCT03744975 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-12-12

No results posted yet for this study

Summary

This study will advance the investigator's knowledge of the integrated cardiorenal and humoral physiology in type 2 diabetic patients with and without pre-clinical diastolic dysfunction, and test a novel therapeutic strategy which may prevent a progression to symptomatic Stage C heart failure

Conditions

  • Diabetes Mellitus, Type 2
  • Diastolic Dysfunction

Interventions

DRUG

LCZ 696

Participants will receive Oral LCZ 696 (Entresto 97/103 mg)

DRUG

Placebos

Participants will receive 1oral Placebo capsule

Sponsors & Collaborators

Principal Investigators

  • Horng H Chen · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2025-08-27
Completion
2025-08-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03744975 on ClinicalTrials.gov